Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of AZD5213 in healthy young and elderly Japanese subjects

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: AZD5213; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• Japan
  • Fukuoka, Japan
    • Research Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures
• Japanese healthy male subjects aged 20 to 45 years (young) and male and female subjects aged 65 to 80 years (elderly)
• Male subjects should be willing to use barrier contraception ie, condoms, from the first day of dosing until 3 months after the last dose of investigational product
• Have a body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no more than 100 kg
• Clinically normal physical findings, supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by the investigator(s)

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, and personality disorder including borderline according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders
• History of psychotic disorder among first degree relatives.
• History of use of antipsychotic, antidepressant or anxiolytic drugs, prescribed as well as non-prescribed use.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Active; Each cohort will have 6 subjects that will receive AZD5213	Drug: AZD5213; Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
Placebo Comparator: Placebo; Each cohort will have 2 subjects that will receive placebo	Drug: Placebo; Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To assess the safety and tolerability of AZD5213 by assessment of adverse event, vital signs, laboratory parameters and electrocardiograms (ECGs).	Range of Days 1-12

Secondary Outcome Measures

Outcome Measure	Time Frame
To assess the PK of AZD5213 after a single and multiple doses by assessment of Cmax.	Range of Days 1-12
To assess the PK of AZD5213 after a single and multiple doses by assessment of fe.	Range of Days 1-12
To assess the PK of AZD5213 after a single and multiple doses by assessment of CLR.	Range of Days 1-12
To assess the PK of AZD5213 after a single and multiple doses by assessment of CL/F.	Range of Days 1-12
To assess the PK of AZD5213 after a single and multiple doses by assessment of t1/2.	Range of Days 1-12
To assess the PK of AZD5213 after a single and multiple doses by assessment of tmax.	Range of Days 1-12
To assess the PK of AZD5213 after a single and multiple doses by assessment of AUC.	Range of Days 1-12

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Study Director: Märta Segerdahl, MD, PhD, AstraZeneca R&D, Södertälje; Principal Investigator: Akimasa Watanabe, MD, Kyushu Clinical Pharmacology Research Clinic, Japan

Publications and helpful links

Helpful Links

• D3030C00004_Clinical_Study_Report_Synopsis.pdf

Study record dates

Study Major Dates

• Study Start: April 1, 2011
• Primary Completion (Actual): October 1, 2011
• Study Completion (Actual): October 1, 2011

Study Registration Dates

• First Submitted: April 13, 2011
• First Submitted That Met QC Criteria: April 13, 2011
• First Posted (Estimate): April 14, 2011

Study Record Updates

• Last Update Posted (Estimate): January 28, 2015
• Last Update Submitted That Met QC Criteria: January 27, 2015
• Last Verified: January 1, 2015

More Information

Terms related to this study

• Keywords: safety; elderly; pharmacokinetics; Japanese; healthy subject; single dose; young; repeated dose; AZD5213
• Other Study ID Numbers: D3030C00004